

YOUNG WOMEN'S FORUM



Managing Breast Cancer
in Young Women

IN CONJUNCTION WITH



VIRTUAL MEETING



27 JULY, 2024



SINGAPORE TIME
14:00 - 19:00 HRS

CONFERENCE E-BROCHURE

Organized by



ywforum.com



MANAGING
BREAST CANCER
IN **YOUNG WOMEN**



TABLE OF **CONTENTS**

WELCOME MESSAGE 04

YWF 2024 FACULTY 05

YWF 2024 AGENDA 10

ACKNOWLEDGMENTS 12

WELCOME MESSAGE

Dear Colleagues,

We are thrilled to extend a warm invitation to the **Young Women's Forum (YWF) 2024**, set to take place on **27 July, 2024** on a virtual format.

Our main theme and commitment remain to addressing the distinct challenges in young women's breast cancer management.

YWF 2024 will explore cutting-edge science, global perspectives, loco-regional protocols with the aim of educating and driving tangible change in the management and treatment of breast cancer in young women.

Join us as we foster collaboration among multidisciplinary teams, discussing challenging cases and creating a platform for meaningful conversations, collaborative learning, and networking with esteemed colleagues.

The committee would like to welcome you all to initiate a meaningful forum to make a difference in young women's life.

We welcome you to the virtual forum to learn and network with your colleagues & peers.

Kind Regards,

YWF 2024 Committee Members



Rebecca Dent
SINGAPORE



Tira Tan
SINGAPORE



Shaheenah Dawood
UAE



Ma Jun
SINGAPORE

MEET THE YWF 2024
FACULTY



YWF 2024 FACULTY



Ava Kwong

Clinical Professor
Chief of Division of Breast Surgery,
Department of Surgery,
The University of Hong Kong
HONG KONG



Elaine Lim

Senior Consultant
Division of Medical Oncology
National Cancer Centre
SINGAPORE



Faye Lim

Senior Consultant Radiation
Oncologist
National Cancer Centre
SINGAPORE



Frances Que

Medical Oncologist
St Luke's Medical Center
PHILIPPINES



Joline Lim

Consultant, Department of
Haematology-Oncology
National University Cancer Institute
SINGAPORE



Kiley Loh

Medical Oncologist
Penang Adventist Hospital
MALAYSIA



Kim Hee Jeong

Breast Cancer Specialist
Asan Medical Center
SOUTH KOREA



Lim Sue Zann

Consultant in Surgical
Oncology, SingHealth Duke-NUS
Breast Centre
SINGAPORE



Ma Jun

Medical Oncologist
National Cancer Centre
SINGAPORE

YWF 2024 FACULTY



Mastura Md Yusof
Cancer Centre Head
Pantai Hospital Kuala Lumpur
MALAYSIA



Matteo Lambertini
Adjunct Professor and Consultant
in Medical Oncology
IRCCS Policlinico San Martino
Hospital - University of Genova
ITALY



Muhammad Azrif
Consultant Clinical Oncologist
Prince Court Medical Centre
MALAYSIA



Nur Diana Ishak
Genetic Counsellor
National Cancer Centre
SINGAPORE



Sabrina Ngaserin
Head of Breast Surgery
Sengkang General Hospital,
SingHealth Duke-NUS
Breast Centre
SINGAPORE



Samuel Ow
Senior Consultant
Medical Oncologist
National University Cancer Institute
SINGAPORE



Sara Tolaney
Chief, Division of Breast Oncology /
Associate Professor of Medicine
Dana-Farber Cancer Institute /
Harvard Medical School
USA



Stephen Johnston
Professor of Breast Cancer Medicine
& Consultant Medical Oncologist
The Royal Marsden NHS
Foundation Trust
UK



**Thitiya Sirisinha
Dejthevaporn**
Assistant Professor
Division of Medical Oncology
Ramathibodi Hospital
Mahidol University
THAILAND

YWF 2024 FACULTY



Timothy Tay

Senior Consultant Pathologist
Singapore General Hospital
SINGAPORE



Tira Tan

Consultant Medical Oncologist
National Cancer Centre
SINGAPORE



Tom Chen

Attending Physician
Department of Oncology
National Taiwan University Hospital
TAIWAN



Yang Liying

Consultant in the Department of
Obstetrics & Gynaecology
SingHealth
SINGAPORE



Yap Yoon Sim

Senior Consultant
National Cancer Centre
SINGAPORE



Zhang Zewen

Medical Oncologist
National Cancer Centre
SINGAPORE

Verzenio is now approved for patients with HR+, HER2-, node positive Early Breast Cancer at high-risk of recurrence.




Although the prognosis for HR+, HER2- early breast cancer (EBC) is generally positive¹


20-30% of patients
could progress to incurable
metastatic disease¹



Factors associated with high risk of recurrence can include²:



Positive
nodal status



High
tumour grade



Large
tumour size



Consider Verzenio for a significant improvement in
invasive disease-free survival for your patients³



References: 1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0. 2. Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare. *Cancer Epidemiol Biomarkers Prev*. 2012;21(5):800-809. 3. N.Harbeck, P.Rastogi et al. (2021). Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Published by Elsevier on behalf of European Society for Medical Oncology.



Verzenio: The only CDK4 & 6 inhibitor that can be taken every day without a planned break (continuous dosing)¹⁻³

150 mg

2 x Daily

The recommended dose of Verzenio is 150 mg twice daily when used in combination with ET¹



References: 1. VERZENIO [Package Insert dated October 2023] Singapore. Eli Lilly (Singapore) Pte Ltd, 2023. Accessed on 20 July 2024. 2. Pfizer Ibrance EPAR July 2021 3. Kisqali EPAR. November 2020



Before prescribing Verzenio (abemaciclib), please consult the full local prescribing information by scanning the following QR code.

SAFETY REPORTING FOR POTENTIAL UNDESIRABLE EFFECTS: Please report adverse events to the DKSH Singapore Pte Ltd at HEC-RA.Sin@dksh.com

Market Expansion
Services by
www.dksh.com



DKSH Singapore Pte Ltd
47 Jalan Buroh, #09-01, Singapore 619491
Phone +65 6471 1466

YWF 2024
AGENDA



YWF 2024 AGENDA



27 JULY, 2024
(SATURDAY)



14:00 - 19:00 HRS
SINGAPORE TIME

14:00 - 14:05	Opening Remarks
SESSION 1: Biological and Clinical Uniqueness of Young Asian Breast Cancer Chairperson: Ma Jun, Singapore	
14:05 - 14:20	Addressing the Unique Needs of Young Women with Breast Cancer: A Call for Comprehensive Care Matteo Lambertini, Italy
14:20 - 14:35	Racial and Ethnic Disparities in Breast Cancer Outcomes for Young Women Yap Yoon Sim, Singapore
14:35 - 14:50	Bridging the Gap with Oncofertility Care Kim Hee Jeong, South Korea
14:50 - 15:00	Q & A
15:00 - 15:30	Breaking Barriers: Redefining Treatment Standards in High-Risk Early Breast Cancer with Abemaciclib - Satellite Symposium by DKSH Chairperson: Elaine Lim, Singapore Speaker: Stephen Johnston, UK
SESSION 2: Navigating the Complexities of Genetic Testing for Hereditary Breast Cancer Syndrome Chairperson: Zhang Zewen, Singapore	
15:30 - 15:45	Genetic Testing in an Ethnically Diverse Asian Country Diana Ishak, Singapore
15:45 - 16:00	Mainstreaming Genetic Testing: Balancing Efficiency and Informed Consent Zhang Zewen, Singapore
16:00 - 16:40	Tumor Board: Hereditary Cancer Syndromes beyond BRCA - Li Fraumeni / Cowden's Moderator: Samuel Ow, Singapore Panellists: Muhammad Azrif, Malaysia Ava Kwong, Hong Kong Faye Lim, Singapore Frances Que, Philippines Nur Diana Ishak, Singapore Sabrina Ngaserin, Singapore Tom Chen, Taiwan
16:40 - 16:55	Q & A
SESSION 3: State of the Art Therapies in Young Women Chairperson: Tira Tan, Singapore	
16:55 - 17:35	Panel Discussion: A Case of Pregnancy Associated Breast Cancer Moderator: Ma Jun, Singapore Panellists: Kiley Loh, Malaysia Thitiya Sirisinha Dejthevaporn, Thailand Yang Liying, Singapore Kim Hee Jeong, South Korea Lim Sue Zann, Singapore
17:35 - 18:05	Fireside chat: Beyond ubiquitous HER2 testing - Making Precision Oncology a Reality for Young Asian Patients Mastura Md Yusof, Malaysia Joline Lim, Singapore Timothy Tay, Singapore
18:05 - 18:20	Making the Case for Proton Beam Therapy in Young Women with Breast Cancer Faye Lim, Singapore
18:20 - 18:35	Incorporating Novel Therapies in Neo(Adj) Therapies for Young Women with Breast Cancer, Immunotherapy, Antibody drug conjugates and more Sara Tolaney, USA
18:35 - 18:50	Q & A
18:50 - 19:00	Closing Remarks

Fighting Strong for Five Years.



KISQALI has accomplished what no other CDK4/6 inhibitor has—the longest median overall survival ever reported in HR+/HER2- aBC.

ESMO-MCBS

Highest score of any CDK4/6 inhibitor in the 1st line¹⁻⁴
(based on OS, PFS, and QoL)
KISQALI + ET in premenopausal patients
KISQALI + AI in postmenopausal patients

NCCN RECOMMENDED

National Comprehensive Cancer Network® (NCCN®) now recognizes ribociclib (KISQALI®) + ET, a Category 1 preferred treatment option, for showing an OS BENEFIT IN THE 1L treatment setting in patients with HR+/HER2- mBC⁵

Superior overall survival vs control arm was proven in MONALEESA-2, MONALEESA-3, and MONALEESA-7.⁶⁻¹²

Indications³

Kisqali is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

- an aromatase inhibitor as initial endocrine-based therapy in pre/perimenopausal or postmenopausal women or in men; or
- fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.

1L, first line; aBC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; ESMO-MCBS, European Society for Medical Oncology Magnitude of Clinical Benefit Scale; ET, endocrine therapy; mBC, metastatic breast cancer; OS, overall survival; PFS, progression-free survival; QoL, quality of life.

References: 1. ESMO MCBS scorecard 158 1. European Society for Medical Oncology. Accessed April 12, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1-2>. ESMO MCBS scorecard 9 1. European Society for Medical Oncology. Accessed April 12, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1-3>. ESMO MCBS scorecard 159 1. European Society for Medical Oncology. Accessed April 12, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-159-1-4>. ESMO MCBS scorecard 7 1. European Society for Medical Oncology. Accessed April 12, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-7-1-5>. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2022. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Published December 20, 2021. Accessed May 9, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. *N Engl J Med.* 2022;386(10):942-950. doi:10.1056/NEJMoa2114663 7. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. *Ann Oncol.* 2021;32(8):1015-1024. doi:10.1016/jannonc.2021.05.353 8. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. *Clin Cancer Res.* 2022;28(5):851-859. doi:10.1158/1078-0432.CCR-21-3032 9. Rugo HS, Finn RS, Dieras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat.* 2019;174(3):719-729. doi:10.1007/s10549-018-05125-4 10. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med.* 2018;379(20):1926-1936. doi:10.1056/NEJMoa1810527 11. Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. *JAMA Oncol.* 2020;6(1):116-124. doi:10.1001/jamaoncol.2019.4782 12. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *npj Breast Cancer.* 2019;5:5. doi.org/10.1038/s41523-018-0097-z 13. KISQALI local product insert May 2022.SINv2



For Healthcare Professionals Only. Please scan this QR code or visit <https://www.novartis.com.sg/product-list/kisqali> to access the full prescribing information.

 **NOVARTIS**

Novartis (Singapore) Pte Ltd

20 Pasir Panjang Road #10-25/28 Mapletree Business City Singapore 117439
Phone: +65 6722 6010

SG2306228733

YWF 2024 **ACKNOWLEDGEMENT**

SPONSOR




CO-SPONSOR



SUPPORTER



SUPPORTED BY



APMEA ONCOLOGY



**APMEA
MOLECULAR™
TUMOR BOARD**

apmeaoncology.com

**IF YOU MISSED ON ANY SESSION
KINDLY VISIT OUR WEBSITE:**

APMEAONCOLOGY.COM

YOUNG WOMEN'S VIRTUAL FORUM 2024

**What can
I expect
from this
platform?**

News and updates from the
world of oncology

Upcoming and archived
webinars

Highlights from recent
conferences

Most recent case and
discussion thread

Podcast and Interview from
experts in Oncology

Organized by



INDEX Holding Headquarters, Road # D-62, Opposite Nad Al Hamar

P.O. Box: 13636, Dubai, United Arab Emirates | Tel: +971 4 520 8888, Fax: +971 4 338 4193

Email: info@ywforum.com, Website: ywforum.com

Continuing the Journey See You in 2025!

    #YWF2024

ywforum.com

Download our MOBILE APP to STREAM LIVE!



Organized by



INDEX® Conferences and Exhibitions Organisation LLC

INDEX Holding Headquarters, Road # D-62, Opposite Nad Al Hamar, P.O. Box: 13636, Dubai, UAE
Tel: +971 4 520 8888, Fax: +971 4 338 4193, Email: info@ywforum.com, Website: ywforum.com